N@N

NuPathe to Present at the Leerink Swann Hot Topics Roundtable Conference

_{//health-fitness.news-articles.net/content/2011/ .. rink-swann-hot-topics-roundtable-conference.html}
^{Published in Health and Fitness on Thursday, February 10th 2011 at 5:40 GMT by Market Wire}  

CONSHOHOCKEN, PA--(Marketwire - February 10, 2011) - NuPathe Inc. (NASDAQ: [ PATH ]), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, today announces that [ Jane Hollingsworth ], chief executive officer, will present a company overview at the Leerink Swann Hot Topics Roundtable Conference on Thursday, February 17, 2011 at 3:20 p.m. EST. The conference is being held at the Roosevelt Hotel in New York.

A live audio webcast of the presentation will be available via the "Investor Relations" page of the NuPathe website, [ www.nupathe.com ]. Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on the Company's website for 90 days following the call.

About NuPathe

NuPathe Inc. ([ www.nupathe.com ]) is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. NuPathe's most advanced product candidate, Zelrix, is a single-use, transdermal sumatriptan patch being developed for the treatment of acute migraine. In addition to Zelrix, NuPathe has two proprietary product candidates in preclinical development: NP201 for the continuous symptomatic treatment of Parkinson's disease, and NP202 for the long-term treatment of schizophrenia and bipolar disorder.